Structured Abstract
Objective To investigate the changes in activity energy expenditure throughout daytime cluster headache attacks in patients with chronic cluster headache, and to evaluate the usefulness of actigraphy as a digital biomarker of cluster headache attacks.
Background Cluster headache is a primary headache disorder characterized by attacks of severe to very severe unilateral head pain with ipsilateral cranial autonomic symptoms and/or a sense of restlessness or agitation. We hypothesized increased activity energy expenditure from hyperactivity during attacks measured by actigraphy.
Methods An observational study including patients with chronic cluster headache was conducted. During 21 days, patients wore an actigraphy device on the non-dominant wrist and recorded cluster headache attack-related data in a dedicated smartphone application. Accelerometer data was used for the calculation of activity energy expenditure before and during daytime cluster headache attacks that occurred in ambulatory settings, and without restrictions on acute and preventive headache treatment. We compared the activity and movements during the pre-ictal, ictal, and postictal phases with data from wrist-worn actigraphy with time-concordant intervals during non-headache periods.
Results Four patients provided 34 attacks, of which 15 attacks met the eligibility criteria for further analysis. In contrast with the initial hypothesis of increased energy expenditure during cluster headache attacks, a decrease in movement was observed during the pre-ictal phase (30 min before onset to onset) and during the headache phase. A significant decrease (p<0.01) in the proportion of high-intensity movement during headache attacks, of which the majority were oxygen-treated, was observed. This trend was less present for low-intensity movements.
Conclusion The results of our analysis may shift the initial hypothesis for future research towards a decrease in activity energy expenditure during the pre-ictal and headache phase of daytime attacks in patients with chronic cluster headache under acute and preventive treatment in ambulatory settings.
Competing Interest Statement
Nicolas Vandenbussche has received travel grants and consulting fees from Novartis AG, TEVA Pharmaceuticals Industries Ltd., AbbVie/Allergan and Pfizer Inc. Koen Paemeleire has received personal compensation from AbbVie/Allergan, Amgen/Novartis AG, Eli Lilly and Company, Lundbeck, Pfizer, Teva Pharmaceuticals Industries Ltd., and Man&Science for consulting, serving on a scientific advisory board, and/or speaking; he and is/was a clinical trial investigator for Almirall (almotriptan),Amgen/Novartis AG (erenumab), Eli Lilly and Company (galcanezumab, lasmiditan), Lundbeck (eptinezumab) and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation). Jonas Van Der Donckt, Mathias De Brouwer, Bram Steenwinckel, Marija Stojchevska, Femke Ongena and Sofie Van Hoecke report no conflicts of interest.
Funding Statement
Nicolas Vandenbussche is funded by Ghent University Hospital 'Fund for Innovation and Clinical Research (Fonds voor Innovatie en Klinisch Onderzoek) 2019' as a PhD Fellow. Jonas Van Der Donckt (1S56322N) is funded by a doctoral fellowship of the Research Foundation Flanders (FWO). Part of this work is done in the scope of the imec.AAA Context-aware health monitoring project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Ghent University Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data is not available.
